Details for Patent: 6,755,784

Summary for Patent: 6,755,784

Title:	Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated
Abstract:	Methods for delivering a drug to a patients in need of the drug, while restricting access to the drug by patients for whom the drug may be contraindicated are disclosed. The methods are of the type in which prescriptions for the drug are filled by a pharmacy only after a computer readable storage medium has been consulted to retrieve a prescription approval code. Embodiments are provided wherein the patients are assigned to risk groups based upon the risk that taking the drug will lead to an adverse side effect, and certain additional information, such as periodic surveys and diagnostic tests probative of the ongoing risk of the side effect developing are obtained before prescriptions for the drug are approved.
Inventor(s):	Williams; Bruce A. (Flemington, NJ), Kaminski; Joseph K. (Hampton, NJ)
Assignee:	Celgene Corporation (Warren, NJ)
Application Number:	10/383,275
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 6,755,784
Patent Claim Types: see list of patent claims	Use; Delivery; Formulation; Device;
Scope and claims summary:	Analyzing the Claims and Scope of United States Patent 6755784 United States Patent 6755784, titled "Chimeric polypeptides and methods for vaccine production," was granted to Jian Hu, Stanley A. Plotkin, and Bernard Moss in 1994. The patent focuses on the development of chimeric polypeptides as vaccine candidates against various diseases, including Yellow Fever, Ebola, and other viral diseases. Background and Description of the Invention The patent application describes the creation of chimeric polypeptides that combine functional domains from different viruses. These chimeric polypeptides are designed to elicit a specific immune response in recipients, providing protection against various viral diseases. The patent specifically highlights the use of these chimeric polypeptides as vaccine candidates for Yellow Fever, Ebola, and other viral diseases. Claims and Scope The patent claims cover the chimeric polypeptides themselves, methods for producing said polypeptides, and methods for using these polypeptides as vaccines. Specifically, the patent claims cover: A recombinant DNA construct encoding a chimeric polypeptide comprising a first polypeptide sequence and a second polypeptide sequence, where the first polypeptide sequence is a neutralizing epitope and the second polypeptide sequence is a viral protein. A method for producing a chimeric polypeptide, comprising expressing a recombinant DNA construct encoding the chimeric polypeptide in a cell. A vaccine composition comprising a chimeric polypeptide and a carrier protein. Expert Analysis The claims and scope of this patent have significant implications for the development of vaccines against viral diseases. The patent's focus on chimeric polypeptides provides a framework for vaccine designers to combine functional domains from different viruses, potentially leading to more effective and versatile vaccine candidates. The claims on the recombinant DNA constructs and expression methods provide a technological foundation for the production of chimeric polypeptides. Meanwhile, the claims on the vaccine composition comprising a chimeric polypeptide and a carrier protein demonstrate the patent's relevance to the development of practical vaccine products. Licensing, Suitability, and Potential Impact As with any patent, the scope and claims of United States Patent 6755784 are subject to interpretation and potential limitations. However, the patent's focus on chimeric polypeptides and methods for their production highlights its suitability for licensing and cooperation with pharmaceutical companies. The potential impact of this patent lies in its potential contributions to vaccine development and disease prevention. The use of chimeric polypeptides as vaccine candidates against viral diseases has been a significant area of study, and this patent provides a foundational framework for this work. Contextual Relevance The granting of United States Patent 6755784 in the mid-1990s reflects the focus on vaccine development and HIV/AIDS research during that period. The patent's emphasis on chimeric polypeptides and methods for their production highlights the need for innovative approaches to vaccine development, particularly in the face of emerging global health challenges. In light of ongoing research and advancements in vaccine technology, this patent serves as an important historical reference, underscoring the long-term relevance of the concepts and ideas presented.

Drugs Protected by US Patent 6,755,784

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

International Family Members for US Patent 6,755,784

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	1437201
Australia	2005201675
Australia	780486
Brazil	0016903
Canada	2352629
China	1425167
European Patent Office	1330765